These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 24521425)
1. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425 [TBL] [Abstract][Full Text] [Related]
2. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077 [TBL] [Abstract][Full Text] [Related]
3. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200 [TBL] [Abstract][Full Text] [Related]
4. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J; PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231 [TBL] [Abstract][Full Text] [Related]
5. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492 [TBL] [Abstract][Full Text] [Related]
7. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722 [TBL] [Abstract][Full Text] [Related]
8. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P; Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305 [TBL] [Abstract][Full Text] [Related]
9. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159 [TBL] [Abstract][Full Text] [Related]
10. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527 [TBL] [Abstract][Full Text] [Related]
11. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209 [TBL] [Abstract][Full Text] [Related]
12. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
13. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623 [TBL] [Abstract][Full Text] [Related]
14. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349 [TBL] [Abstract][Full Text] [Related]
17. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. Strehlau R; Coovadia A; Abrams EJ; Martens L; Arpadi S; Meyers T; Kuhn L J Acquir Immune Defic Syndr; 2012 Aug; 60(4):369-76. PubMed ID: 22134152 [TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children. Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952 [TBL] [Abstract][Full Text] [Related]
20. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]